Literature DB >> 10578588

Penetrating eye injury in war.

J W Biehl1, J Valdez, R K Hemady, S M Steidl, D L Bourke.   

Abstract

The percentage of penetrating eye injuries in war has increased significantly in this century compared with the total number of combat injuries. With the increasing use of fragmentation weapons and possibly laser weapons on the battle-field in the future, the rate of eye injuries may exceed the 13% of the total military injuries found in Operations Desert Storm/Shield. During the Iran-Iraq War (1980-1988), eye injuries revealed that retained foreign bodies and posterior segment injuries have an improved prognosis in future military ophthalmic surgery as a result of modern diagnostic and treatment modalities. Compared with the increasing penetrating eye injuries on the battlefield, advances in ophthalmic surgery are insignificant. Eye armor, such as visors that flip up and down and protect the eyes from laser injury, needs to be developed. Similar eye protection is being developed in civilian sportswear. Penetrating eye injury in the civilian sector is becoming much closer to the military model and is now comparable for several reasons.

Entities:  

Mesh:

Year:  1999        PMID: 10578588

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  3 in total

Review 1.  [Possibilities in the surgical management of eyelid trauma].

Authors:  K J Lipke
Journal:  HNO       Date:  2011-08       Impact factor: 1.284

2.  Incidence and severity of ocular and adnexal injuries during the Second Lebanon War among Israeli soldiers and civilians.

Authors:  Adiel Barak; Amir Elhalel; Joseph Pikkel; Eli Krauss; Benjamin Miller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-12       Impact factor: 3.117

3.  Ophthalmic Combination of SurR9-C84A and Trichostatin-A Targeting Molecular Pathogenesis of Alkali Burn.

Authors:  Kislay Roy; Bhasker Sriramoju; Rupinder K Kanwar; Jagat R Kanwar
Journal:  Front Pharmacol       Date:  2016-07-28       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.